Allspring Global Investments
ENTA icon

Allspring Global Investments’s Enanta Pharmaceuticals ENTA Stock Holding History

Allspring Global Investments’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-95
Closed -$984 – 1969
2024
Q3 		$984 Sell
95
-2,572
-96% -$33.6K ﹤0.01% 2327
2024
Q2 		$34.6K Buy
+2,667
New +$36K ﹤0.01% 2019
2024
Q1 		– Sell
-504
Closed -$4.74K – 2331
2023
Q4 		$4.74K Sell
504
-107
-18% -$997 ﹤0.01% 2060
2023
Q3 		$6.82K Sell
611
-1,569
-72% -$25.3K ﹤0.01% 2655
2023
Q2 		$46.7K Sell
2,180
-352
-14% -$10.4K ﹤0.01% 2309
2023
Q1 		$102K Sell
2,532
-940
-27% -$44.9K ﹤0.01% 2043
2022
Q4 		$162K Sell
3,472
-2,065
-37% -$94.1K ﹤0.01% 1894
2022
Q3 		$287K Buy
5,537
+2,552
+85% +$149K ﹤0.01% 1712
2022
Q2 		$141K Sell
2,985
-14,846
-83% -$806K ﹤0.01% 1939
2022
Q1 		$1.27M Buy
17,831
+2,936
+20% +$191K ﹤0.01% 1747
2021
Q4 		$1.11M Buy
+14,895
New +$1.17M ﹤0.01% 1873

Other funds holding ENTA

KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Allspring Global Investments's ENTA Position: Q4 2024 in Review

Allspring Global Investments sold out of Enanta Pharmaceuticals (ENTA) in Q4 2024, closing a stake of 95 shares — an estimated $984 sold.

Allspring Global Investments first reported a position in ENTA in Q4 2021 and held it in 11 quarters. The position peaked at $1.27M in Q1 2022. 107 funds tracked by Wall St. Rank hold ENTA as of Q4 2024.

  • Allspring Global Investments reported no remaining Enanta Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Allspring Global Investments sold 95 Enanta Pharmaceuticals shares in Q4 2024, an estimated $984.
  • Allspring Global Investments first reported a position in Enanta Pharmaceuticals in Q4 2021 and held it in 11 quarters.
  • Allspring Global Investments's Enanta Pharmaceuticals position peaked at $1.27M in Q1 2022.
  • 107 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2024.

Based on Allspring Global Investments's 13F filing for Q4 2024, filed 29 Jan 2025.